Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667586 | 0.95 | ALOX5 (0.69) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| Trifluoroacetic Acid SCHEMBL6465764 | 0.91 | ALOX5 (0.52) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1727025 | 0.90 | KMT2A (0.62) | ALOX5HDAC2HDAC8HDAC6NPC1 | |
| SCHEMBL30765759 | 0.88 | ALOX5 (0.57) | ALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL5321740 | 0.84 | ALOX5 (0.55) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13792415 | 0.84 | ALOX5 (0.77) | ALOX5KMT2AALDH1A1 | |
| SCHEMBL9835455 | 0.83 | ALOX5 (0.61) | ALOX5HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8358797 | 0.83 | CYP2D6 (0.58) | ALDH1A1 | |
| SCHEMBL3868251 | 0.83 | HSD17B10 (0.59) | ALOX5MAPK1TDP1KMT2A | |
| SCHEMBL8493143 | 0.82 | ALOX5 (0.69) | ALOX5HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143425-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2099761-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| US-20060079562-A1 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-13 | — | — | US | disclosed |
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6300337-B1 | Acetamide derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-10-09 | — | — | US | disclosed |
| US-6271238-B1 | USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-1055683-A1 | NOVEL ACETAMIDE DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-11-29 | — | — | EP | disclosed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | ALOX5 74/4885HDAC3 247/4885HDAC1 1087/4885 |
| US-20060079562-A1 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | GHRHR, GHSR, NPY1R | ALOX5 3938/4885HDAC3 1840/4885HDAC1 1094/4885 |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | ALOX5 780/4885HDAC3 1585/4885HDAC1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.